Muscarinic Antagonists/adverse effects

Requena, G., Czira, A., Banks, V., Wood, R., Tritton, T., Castillo, C., et al. (2023). Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England. Int J Chron Obstruct Pulmon Dis, 18, 2039-2054. http://doi.org/10.2147/copd.s408688

View

Halpin, D. M. G., Rothnie, K. J., Banks, V., Czira, A., Compton, C., Wood, R., et al. (2022). Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting. Int J Chron Obstruct Pulmon Dis, 17, 2417-2429. http://doi.org/10.2147/copd.s370540

View

Rebordosa, C., Plana, E., Rubino, A., Aguado, J., Martinez, D., Lei, A., et al. (2022). Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists. Int J Chron Obstruct Pulmon Dis, 17, 1715-1733. http://doi.org/10.2147/copd.s363997

View

Sansbury, L. B., Rothnie, K. J., Bains, C., Compton, C., Anley, G., & Ismaila, A. S. (2021). Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England. Int J Chron Obstruct Pulmon Dis, 16, 2591-2604. http://doi.org/10.2147/copd.s318969

View